MBX Biosciences (MBX) Cash & Equivalents (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Cash & Equivalents data on file, last reported at $45.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 51.2% year-over-year to $45.2 million; the trailing twelve-month figure through Mar 2026 stood at $45.2 million (up 51.2% YoY), and the FY2025 full-year result was $75.3 million, up 52.56% from the prior year.
• Cash & Equivalents fell to $45.2 million in Q1 2026, from $75.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $223.1 million in Q3 2025 to a low of $29.9 million in Q1 2025.
• A 4-year average of $78.3 million and a median of $47.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 67.93% in 2025 and soared 51.2% in 2026, its largest moves.
• Tracing MBX's Cash & Equivalents over 4 years: stood at $30.5 million in 2023, then surged by 61.68% to $49.4 million in 2024, then surged by 52.56% to $75.3 million in 2025, then slumped by 39.95% to $45.2 million in 2026.
• Business Quant data shows MBX's Cash & Equivalents at $45.2 million in Q1 2026, $75.3 million in Q4 2025, and $223.1 million in Q3 2025.